BRIEF

on Adolore Biotherapeutics, Inc.

Adolore BioTherapeutics to Present at 18th Annual Pain Therapeutics Summit

DELRAY BEACH, FL / ACCESSWIRE / October 2, 2024 / Adolore BioTherapeutics, a company focused on developing opioid-free treatments for chronic pain, announced today that Dr. Roy C. Levitt will present at the 18th Annual Pain Therapeutics Summit. The summit will take place on October 28-29, 2024 in Boston, MA.

Dr. Levitt, the founder and Chief Medical Officer of Adolore, will discuss the company's innovative CA8* chronic pain therapeutics. These therapies utilize disease-free, nontoxic replication-defective Herpes Simplex Virus (rdHSV) vectors for intracellular delivery. The company is progressing its lead programs, ADB-101 and ADB-102, towards investigational new drug filings and human clinical studies.

The development program for chronic pain due to knee osteoarthritis is supported by an NIH/NINDS HEAL UH3 Award, funding preclinical studies through to human trials expected to start in 2026.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Adolore Biotherapeutics, Inc. news